Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions) I'll now hand the ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...